Leerink Partners Issues Pessimistic Forecast for Incyte (NASDAQ:INCY) Stock Price

Incyte (NASDAQ:INCY) had its target price reduced by analysts at Leerink Partners from $154.00 to $150.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Partners‘s price target indicates a potential upside of 25.37% from the company’s previous close.

A number of other equities analysts have also commented on INCY. Truist Financial raised their price target on Incyte from $105.00 to $115.00 and gave the stock a “hold” rating in a report on Wednesday, October 14th. BMO Capital Markets reiterated a “market perform” rating on shares of Incyte in a research note on Tuesday, October 27th. UBS Group set a $152.00 price objective on Incyte in a report on Friday, October 30th. Barclays raised their target price on Incyte from $139.00 to $143.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Incyte in a report on Tuesday, October 27th. Twelve equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $132.86.

Incyte Price Performance

Shares of INCY traded up $1.64 during trading hours on Thursday, hitting $119.65. The company’s stock had a trading volume of 1,486,170 shares, compared to its average volume of 1,891,601. The business has a 50 day simple moving average of $119.62 and a two-hundred day simple moving average of $108.51. Incyte has a 52-week low of $89.25 and a 52-week high of $132.60. The company has a market cap of $24.39 billion, a price-to-earnings ratio of 63.64, a PEG ratio of 4.50 and a beta of 0.78.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping the consensus estimate of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The company had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same period last year, the firm earned $2.26 EPS. Incyte’s revenue for the quarter was up 14.0% on a year-over-year basis. Research analysts predict that Incyte will post 2.24 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Thomas Tray sold 610 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total transaction of $72,565.60. Following the completion of the transaction, the insider directly owned 21,126 shares in the company, valued at $2,513,148.96. The trade was a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo J. Cagnoni sold 2,642 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $112.71, for a total value of $297,779.82. Following the completion of the transaction, the insider owned 183,200 shares in the company, valued at $20,648,472. This represents a 1.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 14,053 shares of company stock worth $1,726,519 in the last quarter. 16.20% of the stock is currently owned by company insiders.

Institutional Trading of Incyte

A number of large investors have recently modified their holdings of the business. Trails Edge Capital Partners LP bought a new position in shares of Incyte in the 2nd quarter worth $17,570,800. Twin Capital Management Inc. bought a new stake in shares of Incyte during the 1st quarter worth $875,000. Tidal Investments LLC lifted its holdings in shares of Incyte by 33.4% during the 2nd quarter. Tidal Investments LLC now owns 102,834 shares of the biopharmaceutical company’s stock worth $11,657,000 after acquiring an additional 25,768 shares during the last quarter. BlackRock Inc. purchased a new position in Incyte in the second quarter worth $2,044,189,000. Finally, Mediolanum International Funds Ltd grew its position in Incyte by 25.4% in the first quarter. Mediolanum International Funds Ltd now owns 60,300 shares of the biopharmaceutical company’s stock worth $5,447,000 after acquiring an additional 12,227 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Leerink Partners reaffirmed its Buy rating and set a $150 price target, indicating confidence in Incyte’s prospects. Article
• Positive Sentiment: Incyte plans to present new hematology data at ASH 2026. Canaccord Genuity maintained its Buy rating and $152 target, citing upcoming data for ’989 as support for its view; the results could provide updates on pipeline potential. Article Analyst report
• Neutral Sentiment: Incyte raised Bernstein’s price target to $108 from $104. The increase is modest, and the new target remains below the recent share price. Article
• Neutral Sentiment: The company awarded grants supporting projects focused on graft-versus-host disease (GVHD). The program underscores its engagement in the area but is unlikely to materially affect near-term revenue. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, retaining more than 21,000 shares afterward. The planned, relatively small sale offers limited directional signal. Article

Incyte Company Profile

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.